Business
Alvotech Publishes 2025 Annual Report
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is available in the
About this update from Alvotech
REYKJAVIK, ICELAND ( March 30, 2026 ) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is available in the investor relations section of Alvotech’s website at: https://investors.alvotech.com/financials and is attached to this announcement in PDF and iXBRL formats. For further information, contact: Media Benedikt Stefansson Sarah MacLeod [email protected] Investors Dr. Balaji V Prasad (US) Patrik Ling (SE) Benedikt Stefansson (IS) [email protected] About Alvotech Alvotech is a biotechnology company, founded by Robert Wessman , focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States , Europe , Japan , China , and other Asian countries and large parts of South America , Africa and the Middle East . For more information, please visit https://www.alvotech.com . None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram and YouTube . Attachments Alvotech Consolidated Financial Statements FY 2025 222100DCZBOWV5DZ8372-2025-12-31-1-en